ID   UT-SCC-16A
AC   CVCL_7812
SY   University of Turku-Squamous Cell Carcinoma-16A
DR   Cosmic; 1140774
DR   Cosmic; 1219858
DR   GEO; GSM2883360
DR   GEO; GSM2888823
DR   IARC_TP53; 11064
DR   Wikidata; Q54992071
RX   DOI=10.1158/1538-7445.AM2020-507;
RX   PubMed=8725545;
RX   PubMed=8782485;
RX   PubMed=9187133;
RX   PubMed=11799138;
RX   PubMed=15287027;
RX   PubMed=17312569;
RX   PubMed=29970484;
RX   PubMed=30135316;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Caution: UT-SCC-16A and UT-SCC-16B are supposed to originate from the same patient but have totally different STR profiles.
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
ST   Source(s): PubMed=30135316
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 9,12
ST   D18S51: 12,16
ST   D19S433: 13,16
ST   D21S11: 30.2
ST   D2S1338: 17,25
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 9,13
ST   FGA: 20
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 17,18,19,20
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7813 ! UT-SCC-16B
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 17
//
RX   DOI=10.1158/1538-7445.AM2020-507;
RA   Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J.,
RA   Koritzinsky M., Wouters B.G.;
RT   "Repurposing of FDA approved drugs for treatment of metastatic HNSCC.";
RL   Cancer Res. 80 Suppl. 16:507-507(2020).
//
RX   PubMed=8725545; DOI=10.3109/00016489609137854;
RA   Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.;
RT   "Increased radiosensitivity is associated with p53 mutations in cell
RT   lines derived from oral cavity carcinoma.";
RL   Acta Oto-Laryngol. 116:341-344(1996).
//
RX   PubMed=8782485; DOI=10.1046/j.1365-2184.1996.01009.x;
RA   Servomaa K., Kiuru A., Grenman R., Pekkola-Heino K., Pulkkinen J.O.,
RA   Rytomaa T.;
RT   "p53 mutations associated with increased sensitivity to ionizing
RT   radiation in human head and neck cancer cell lines.";
RL   Cell Prolif. 29:219-230(1996).
//
RX   PubMed=9187133;
RA   Soukka T., Salmi M., Joensuu H., Hakkinen L., Sointu P., Koulu L.,
RA   Kalimo K., Klemi P., Grenman R., Jalkanen S.T.;
RT   "Regulation of CD44v6-containing isoforms during proliferation of
RT   normal and malignant epithelial cells.";
RL   Cancer Res. 57:2281-2289(1997).
//
RX   PubMed=11799138; DOI=10.1177/002215540205000207;
RA   Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.;
RT   "Splicing mutations in TP53 in human squamous cell carcinoma lines
RT   influence immunohistochemical detection.";
RL   J. Histochem. Cytochem. 50:197-204(2002).
//
RX   PubMed=15287027; DOI=10.1002/gcc.20066;
RA   Takebayashi S., Hickson A., Ogawa T., Jung K.-Y., Mineta H., Ueda Y.,
RA   Grenman R., Fisher S.G., Carey T.E.;
RT   "Loss of chromosome arm 18q with tumor progression in head and neck
RT   squamous cancer.";
RL   Genes Chromosomes Cancer 41:145-154(2004).
//
RX   PubMed=17312569; DOI=10.1002/hed.20478;
RA   Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L.,
RA   Koch W.M., Ferris R.L., Lai S.Y.;
RT   "Head and neck squamous cell carcinoma cell lines: established models
RT   and rationale for selection.";
RL   Head Neck 29:163-188(2007).
//
RX   PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733;
RA   Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A.,
RA   Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M.,
RA   Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.;
RT   "Drug-sensitivity screening and genomic characterization of 45
RT   HPV-negative head and neck carcinoma cell lines for novel biomarkers
RT   of drug efficacy.";
RL   Mol. Cancer Ther. 17:2060-2071(2018).
//
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
//